logo-loader
viewReNeuron Group PLC

ReNeuron publishes positive pre-clinical data from its retinitis pigmentosa programme

In keeping with its policy of putting the results of pre-clinical work in the public domain for review by scientists, ReNeuron Group Plc (LON:RENE) has published positive data regarding its cell therapy for retinitis pigmentosa (RP), an inherited disease that can cause blindness.

Michael Hunt, chief financial officer (CFO), tells Proactive Investors that ReNeuron “is very keen to put what we do in the public domain … where the data are available for review by others."

The publication relates to data that was part of the pre-clinical package that was put before the US Food and Drug Administration (FDA); ReNeuron recently kicked off a Phase I/II clinical trial in the US to evaluate the safety, tolerability and preliminary efficacy of its human retinal progenitor cells.

“It’s quite a small initial first-in-man study,” Hunt revealed, adding that these sorts of studies normally are small.

“We’re sort of off the starting blocks and we’re treating patients now,” the CFO said.

Hunt also reiterates some previously announced timelines on the US study. RP has been given orphan status, so the clinical development pathway should be swifter than it is for what might be termed more mainstream drugs.

Quick facts: ReNeuron Group PLC

Price: 135 GBX

LSE:RENE
Market: LSE
Market Cap: £42.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating...

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott following the release of new positive data relating to its CTX cell therapy candidate which has been published in the peer-reviewed scientific journal Stem Cells. He says the new data shows for the first...

2 weeks, 6 days ago

2 min read